Rsv

Pic:getty/sohelparvezhaque

Pfizer acquires RSV therapeutic candidates

By Rachel Arthur

Pfizer will acquire ReViral, a privately-held clinical-stage company which is focused on novel antiviral therapeutics for respiratory syncytial virus (RSV), for up to $525m.

Pic:getty/coffeekai

Moderna initiates Phase 3 trial for RSV vaccine candidate

By Rachel Arthur

Moderna has initiated the Phase 3 portion of its pivotal respiratory syncytial virus (RSV) vaccine trial: looking towards its ultimate goal to combine the vaccine with its COVID-19 and flu boosters into a single dose booster.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers